It is Not 8.00 the challenge, it is rather the 8.50 - 12.00 range
This should be nicely handled by official FDA expedited approval (separate announcement) and partnership appetites are bit too whetted not to jump in at risk (but not really) to partner not one iota to Celldex
Your right about the price range. When I bought a few years ago in the 9's at ASCO. We've come so much further. The price we are at now is ridiculous. We should be at least 9-10 dollars easily. That's when we had the PFE debacle.
...And it reached an intraday high in June 2008 of 19.00+ based upon partnership with Rindo in phase 1 with Pfizer, amazing, eh?! (of course its base was higher at the time prior to Pfizer marriage to Rindo but still, quite ABSURD
I prefer not to see a PT re 011. I know the conventional wisdom is that CLDX cannot go it alone, but that is where the real money will be made. If it needs to take in a partner I would prefer to see a merger with with a company like DNDN assuming it can turn Provnege around and become profitable. or some similar sized company.
No matter what position AM thinks he holds any deal with Big pharma will leave cldx shareholder with crums in comparison to the long-term value of 011.
I agree. Perhaps a spin-off and merger within a given genre (i.e., CDX-011) or on certain indications therein. The entirety of this pipeline no one can get their heads/hand around. It is almost like an independent living breathing Gestalt, organic entity, lol Partnership(s) perhaps, bread crumbs less likely, especially if partnerships are on certain sectors or certain sectors of pipelines. If Pfizer was not Pfizer, and instead had the foresight, insight, any hindsight, lol then breadcrumbs on Rindo, when all would have been said and done (90M upfront 300M in royalties)
would perhaps have been the case. They are not stupid. They know what they are holding!